Drugs / [68Ga]Ga-PSMA-11
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06462508 | Apr 2024 → Jun 2025 | prostate cancer | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05955677 | Jul 2023 → Jul 2024 | prostate cancer | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06379217 | Jul 2024 → Aug 2026 overdue | prostate neuroendocrine neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04838613 | Sep 2021 → Nov 2023 | prostate cancer | Novartis Pharmaceuticals | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05658003 Background | May 2023 → Dec 2024 overdue | prostate carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-PSMA-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06462508 ↗ |
| Modality | Diagnostic / imaging agent | “imaging, including at least 1 contrast-enhanced CT scan and 1 [68Ga]Ga-PSMA-11 PET/CT scan” PMID 40473464 ↗ Aug 2025 |
| Route | Intravenous | “Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan” NCT04838613 ↗ |